SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
Ann R. Falsey(University of Rochester), Robert W. Frenck(Cincinnati Children's Hospital Medical Center), Edward E. Walsh(University of Rochester), Nicholas Kitchin(Pfizer (United States)), Judith Absalon(Pfizer (United States)), Alejandra Gurtman(Pfizer (United States)), Stephen Lockhart(Pfizer (United Kingdom)), Ruth Bailey(Pfizer (United Kingdom)), Kena A. Swanson(Pfizer (United States)), Xia Xu(Pfizer (United States)), Kenneth Koury(Pfizer (United States)), Warren V. Kalina(Pfizer (United States)), David Cooper(Pfizer (United States)), Jing Zou(The University of Texas Medical Branch at Galveston), Xuping Xie(The University of Texas Medical Branch at Galveston), Hongjie Xia(The University of Texas Medical Branch at Galveston), Özlem Türeci(BioNTech (Germany)), Eleni Lagkadinou(BioNTech (Germany)), Kristin R. Tompkins(Pfizer (United States)), Pei‐Yong Shi(The University of Texas Medical Branch at Galveston), Kathrin U. Jansen(Pfizer (United States)), Uğur Şahin(BioNTech (Germany)), Philip R. Dormitzer(Pfizer (United States)), William C. Gruber(Pfizer (United States))
Cited by 418Open Access
Abstract
Immune Response to a Third Dose of BNT162b2 A third dose of the BNT162b2 vaccine was administered to 23 volunteers 8 to 9 months after the second dose, and the immune response was assessed. Local r...
Related Papers
No related papers found
Powered by citation graph analysis